Navigation Links
Immucor Closes BioArray Acquisition
Date:8/5/2008

NORCROSS, Ga., Aug. 5 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced today that it has closed its previously-announced acquisition of BioArray Solutions Ltd.

Gioacchino De Chirico, President & CEO of Immucor, said, "We are pleased to have completed this acquisition, which we believe will enable us to provide innovative molecular diagnostic solutions for blood transfusions to enhance patient outcomes."

Immucor expects to provide more information about the BioArray acquisition on its investors conference call in October to review the results of its first fiscal quarter.

Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of our market segments.

For more information on Immucor, please visit our website at http://www.immucor.com .

Statements contained in this press release that are not statements of historical fact are "forward-looking statements" as that term is defined under federal securities laws, including, without limitation, all statements concerning Immucor's expectations, beliefs, intentions or strategies for the future. Factors related to the BioArray acquisition that could adversely affect the Company's results include but are not limited to: the ability of the Company to successfully develop an automated platform for BioArray's transfusion genotyping system, and the cost to do so; the ability of the Company to gain FDA clearance for that automated platform; the acceptance of BioArray technology in transfusion and transplantation markets; and the cost to successfully market and sell products incorporating BioArray technology. Further risks concerning the Company's business are detailed in the Company's filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on any forward-looking statements. Immucor assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Immucor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Immucor Schedules Fiscal 2009 Guidance Call
2. Immucor Responding to FDA Warning Letter
3. Immucor Announces Record Fiscal Third Quarter Results
4. Immucor Schedules Third Quarter Earnings Release and Conference Call
5. Immucor, Inc. Adds Director to Board
6. Immucor Announces Update to Second Quarter Conference Call Number
7. Immucor, Inc. Appoints New Chief Financial Officer
8. Immucor Announces Record Fiscal First Quarter Revenues
9. Immucor Schedules First Quarter Earnings Release and Conference Call
10. NBTY Closes on Purchase of Leiner Health Products
11. Retired Respironics Chairman Jerry McGinnis and Renal Solutions CEO Pete DeComo Join ALung Technologies Board of Directors; ALung Closes on $1 Million Bridge Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between ... they no longer use or need, from clothes to couches to dressers and bicycles. ... and take them to the nearest Goodwill donation center through February 28th. , ...
(Date:1/20/2017)... Miami, Florida (PRWEB) , ... January 20, 2017 , ... ... in head lice cases in families with school-aged children since the holiday season. ... spend the holidays with their families, sharing hugs and taking photos, which is the ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... its sugar-free alternative VW+ 002. The drinks have been produced in collaboration with ... to perform during your workout. , After a successful launch in Sweden last ...
(Date:1/20/2017)... ... 2017 , ... D R Burton Healthcare Products LLC, makers ... in a study indicating superior performance against competitive products in secretion clearance. ... Positive Expiratory Pressure Devices During Simulated Breathing“ was published in the winter issue ...
(Date:1/20/2017)... ... January 20, 2017 , ... “God's Miracle Man: Against All Odds”: an ... of published author, Keith C. A. Tucker, son of Minister Delores Pinnock and a ... by Reverend Mark Hardy , “While sitting up in bed, I felt a pounding ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 19, 2017 Shire plc (LSE: ... U.S. Food and Drug Administration (FDA) has acknowledged receipt ... Application (NDA) for SHP465, a long-acting, triple-bead, mixed amphetamine ... once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is ... 20, 2017, the designated Prescription Drug User Fee Act ...
(Date:1/19/2017)... 19, 2017 Pfizer joins ... Milner Therapeutics Consortium   Major research ... Cambridge   The Milner Therapeutics ... ) as a partner to the Milner Therapeutics Consortium. ... the efficient transfer of materials between industry and academia ...
(Date:1/19/2017)... Florida , January 19, 2017 ... Trump administration appears serious about reducing the FDA,s ... and innovation in the medical drug industry, many ... ahead with new clinical trials and development of ... companies forging ahead with recent developments include:  Moleculin ...
Breaking Medicine Technology: